Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
8
×
life sciences
national
8
×
national blog main
national top stories
new york blog main
new york top stories
pfizer
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
startups
cancer
deals
fda
alzheimer's disease
eli lilly
merck
alexion pharmaceuticals
astrazeneca
bristol-myers squibb
What
bio
roundup
drug
develop
alzheimer’s
amid
bombast
cancer
caught
companies
coronavirus
debate
discussion
efforts
growing
meso’s
miss
new
pandemic
pfizer’s
pharmaceutical
plan
presidential
prices
promise
response
tuesday’s
typically
vaccine
viewers
advantages
alliance
annual
approved
assessed
attention
bails
bar
biotech
brand
Language
unset
Current search:
investing
×
pfizer
×
national
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More